RESUMO
Soria, M, Ansón, M, Lou-Bonafonte, JM, Andrés-Otero, MJ, Puente, JJ, and Escanero, J. Fat oxidation rate as a function of plasma lipid and hormone response in endurance athletes. J Strength Cond Res 34(1): 104-113, 2020-Plasma lipid changes during incremental exercise are not well known. The aim of this study was to investigate the relationship among fat oxidation rate, plasma lipids, and hormone concentrations in well-trained athletes. Twenty-six trained triathletes completed a graded cycle ergometer test to exhaustion increasing by 0.5 W·kg every 10 minutes. Fat oxidation rates were determined using indirect calorimetry. For each individual, maximal fat oxidation (MFO), the intensity at which MFO occurred (Fatmax), and the intensity at which fat oxidation became negligible (Fatmin) were determined. Blood samples for lipids and hormones analysis were collected at the end of each stage of the graded exercise test. All variables studied except insulin showed an increase at the end of incremental protocol with respect to basal levels. Free fatty acid reached significant increase at 60%VO2max and maximal levels at 70%VO2max. Low-density lipoprotein (LDL) and triglycerides (TG) decreased and showed lowest levels at 60%VO2max and reaching significant increases after 80%VO2max. High-density lipoprotein reached significant increase at 60%VO2max. Adrenaline and noradrenaline increased until the end of the incremental exercise, and significant differences were from 50%VO2max. These results suggest that exercise intensities are related to plasma lipids levels. In the zone when lipids oxidation is maximal, plasma LDL and TG variation differs from other lipids. These results may have application for the more adequate exercise intensity prescription to maximize the beneficial effects of exercise.
Assuntos
Tecido Adiposo/metabolismo , Hormônios/sangue , Metabolismo dos Lipídeos , Lipídeos/sangue , Resistência Física , Adulto , Atletas , Calorimetria Indireta , Catecolaminas/sangue , Ergometria , Exercício Físico/fisiologia , Teste de Esforço , Ácidos Graxos não Esterificados/sangue , Humanos , Insulina/sangue , Masculino , Oxirredução , Consumo de OxigênioRESUMO
BACKGROUND: Type 2 diabetes has been described to be associated with hypothyroidism but we recently found that a decrease in pituitary sensitivity to thyroid hormone is associated with diabetes, obesity, and the metabolic syndrome.We aim to assess the longitudinal nature of this association in the population-based Study of Health in Pomerania(SHIP) in Germany. MATERIALS AND METHODS: 77% of a population-based sample of 4308 participants between 20 and 79 years was followed for 5 years. We studied 2542 participants without diabetes or thyroid medication at baseline and complete data in the variables of interest. Data of baseline thyroxine(fT4) and thyrotropin(TSH) were used to calculate the Parametric Thyroid Feedback Quantile-based Index(PTFQI), which measures whether TSH remains elevated despite fT4 being high. It uses the average population response as reference. PTFQI association with incidence of type 2 diabetes over 5 years was estimated with Poisson regression models adjusted for age, sex, and body mass index(BMI). RESULTS: Compared with the 1st PTFQI quartile, Incidence Rate Ratios (IRR) for diabetes were 1.54(95% CI 0.97 to 2.46), 1.55(0.94 to 2.57), and 1.97(1.27 to 3.10) for the upper quartiles (p-trend=0.004) after adjusting for age and sex. The association remained statistically significant after additionally adjusting for BMI: 1.64(1.05 to 2.59) for the 4th vs the 1st quartile (p-trend=0.043). CONCLUSIONS: An elevation of the pituitary TSH-inhibition threshold is associated with incident type 2 diabetes independently of BMI. The PTFQI might have clinical potential for prognosis and metabolic status monitoring.
RESUMO
Introduction: Atrial fibrillation is associated with hyperthyroidism. Within the euthyroid range, it is also associated with high thyroxine (fT4), but not with thyrotropin (TSH). We aim to describe differences in thyroid regulation, measured by the Parametric Thyroid Feedback Quantile-Based Index (PTFQI), between patients with atrial fibrillation and the general population. Materials and methods: Thyroid parameters (PTFQI, TSH, and fT4) of a sample of 84 euthyroid subjects with atrial fibrillation (cases) were compared to a reference sample of euthyroid healthcare patients (controls). We calculated age and sex adjusted ORs for atrial fibrillation across tertiles of these parameters. Also, within cases, we studied thyroid parameters association with clinical characteristics of the atrial fibrillation. Results: After adjusting for age and sex, fT4 and PTFQI were higher in subjects with atrial fibrillation when compared to the general sample (p<0.01 and p=0.01, respectively). Atrial fibrillation ORs of the third versus the first PTFQI tertile was 1.88(95%CI 1.07,3.42), and there was a gradient across tertiles (p trend=0.02). Among atrial fibrillation patients, we observed that higher PTFQI was associated with sleep apnea/hypopnea syndrome (OSAS) (p=0.03), higher fT4 was associated with the presence of an arrhythmogenic trigger (p=0.02) and with heart failure (p<0.01), and higher TSH was also associated with OSAS (p<0.01). Conclusions: Euthyroid subjects with atrial fibrillation have an elevation of the pituitary TSH-inhibition threshold, measured by PTFQI, with respect to the general population. Within atrial fibrillation patients, high PTFQI was associated with OSAS, and high fT4 with heart failure. These results hint of the existence of a relationship between thyroid regulation and atrial fibrillation.
Assuntos
Fibrilação Atrial , Hipertireoidismo , Humanos , Testes de Função Tireóidea/métodos , Retroalimentação , Tireotropina , Hipertireoidismo/epidemiologiaRESUMO
Background: The usual inverse correlation between thyrotropin (TSH) and thyroid hormone disappears in syndromes of central resistance to thyroid hormone, where both are high. TSH and thyroid hormone are also simultaneously high when there is an elevation of the set point of the thyroid regulation axis. This can be estimated with indices, such as the Parametric Thyroid Feedback Quantile-based Index (PTFQI), which was designed for the general population. The PTFQI is positively associated with diabetes prevalence, but association with other pathologies has not been yet explored. The aim of this project was to explore the potential relationship of the PTFQI with metabolic and cardiovascular disease in a sample of ambulatory adult patients from Spain. Methods: A cross-sectional study was carried out among the patients who underwent thyroid hormones measurement (6434 measurements from September to November 2018 in a central laboratory in Spain). We retrospectively reviewed clinical records of a subgroup of adults aged >18 years with normal TSH and free thyroxine (fT4) belonging to groups that represent extreme PTFQI (n = 661). Individuals with known conditions interfering the thyroid axis were excluded (remaining n = 296). Logistic and linear regression models adjusted for age and sex were used to calculate odds ratio (OR) of diseases and differences of clinical parameters, and 95% confidence intervals [CI]. Results: Across levels with higher PTFQI, there was an increase in the prevalence of type 2 diabetes (High vs. Low PTFQI OR: 2.88 [CI: 1.14-7.86], p-Trend = 0.02), ischemic heart disease (16.4% vs. 0%, unadjusted Haldane-Anscombe corrected OR: 23.90 [CI: 1.36-21.48], adjusted p-Trend = 0.04), atrial fibrillation (OR: 8.13 [CI: 1.33-158.20], p-Trend = 0.05), and hypertension (OR: 3.19 [CI: 1.14-9.94], p-Trend = 0.05). While the prevalence of type 2 diabetes was similarly associated with TSH and fT4, ischemic heart disease, atrial fibrillation, and hypertension were more strongly associated with the differences in fT4 values. Conclusions: Type 2 diabetes, ischemic heart disease, atrial fibrillation, and hypertension may be associated with a higher central regulation set point for thyroid hormone. These findings should be confirmed in other populations.
Assuntos
Fibrilação Atrial , Doenças Cardiovasculares , Diabetes Mellitus Tipo 2 , Hipertensão , Isquemia Miocárdica , Adulto , Humanos , Estudos Transversais , Tiroxina , Doenças Cardiovasculares/epidemiologia , Diabetes Mellitus Tipo 2/epidemiologia , Retroalimentação , Estudos Retrospectivos , Tireotropina , Testes de Função Tireóidea , Hormônios TireóideosRESUMO
PURPOSE: Compaction of particulated grafts is done manually; thus, the effect of compression force on bone regeneration remains unclear. The aim of this study was to evaluate the impact of two different compression forces on the consolidation of particulated bovine hydroxyapatite. MATERIALS AND METHODS: Two titanium cylinders were fixed on the calvarium of eight New Zealand rabbits. Both defects were filled with particulated bovine hydroxyapatite subjected to a compression force of 0.7 kg/cm2 or 1.6 kg/cm2 before being covered with a resorbable collagen membrane. A handheld device that uses a spring to control the compression force applied by the plugger was used. At 6 weeks, histomorphometry of the area immediately adjacent to the calvaria bone and to the collagen membrane was performed. RESULTS: It was shown that next to the calvaria, the bone volume per tissue volume (BV/TV) was 29.0% ± 8.8% and 27.6% ± 8.2% at low and high compression force, respectively; the bone-to-biomaterial contact (BBC) was 58.2% ± 25.0% and 69.3% ± 22.9%, respectively (P > .05). In the corresponding area next to the collagen membrane, BV/TV was 4.9% ± 5.1% and 5.7% ± 4.7%, and the BBC was 18.3% ± 20.8% and 20.1% ± 15.9%, respectively (P > .05). In addition, the number and area of blood vessels were not significantly affected by compression force. CONCLUSION: Both compression forces applied resulted in similar consolidation of bovine hydroxyapatite expressed by new bone formation and vascularization based on a rabbit calvaria augmentation model.
Assuntos
Regeneração Óssea , Durapatita , Animais , Materiais Biocompatíveis , Bovinos , Colágeno , Coelhos , Crânio/cirurgiaRESUMO
Cisplatin accumulates in mitochondria, which are a major target for this drug in cancer cells. Thus alterations in mitochondrial function have been implicated in cancer cell resistance to chemotherapeutic agents. Moreover, cisplatin toxic side effects seem to be associated with mitochondrial injury in vivo and in vitro. In order to clarify the potential effect of cisplatin in mtDNA (mitochondrial DNA) maintenance and expression, we have analysed rat liver mtDNA and mtRNA (mitochondrial RNA) synthesis as well as their stability under the influence of in vivo treatment or in vitro exposure to cisplatin. We show that cisplatin causes a direct and significant impairment of mtDNA and mtRNA synthesis and decreases steady-state levels of mtRNAs in isolated mitochondria. Furthermore, in vivo treatment of the animals with cisplatin exerts a protective effect from the impairment of mtRNA metabolism caused by in vitro exposure to the drug, by means of increased mitochondrial GSH levels after in vivo cisplatin treatment.
Assuntos
Cisplatino/farmacologia , DNA Mitocondrial/metabolismo , Glutationa/metabolismo , Animais , DNA Mitocondrial/antagonistas & inibidores , DNA Mitocondrial/genética , Glutationa/genética , Fígado/efeitos dos fármacos , Fígado/metabolismo , RNA/antagonistas & inibidores , RNA/genética , RNA/metabolismo , RNA Mitocondrial , Ratos , Ratos WistarRESUMO
OBJECTIVE: Diabetes prevalence and incidence increase among individuals with hypothyroidism but also among those with hyperthyroxinemia, which seems contradictory. Both high free thyroxine (fT4) and high thyroid-stimulating hormone (TSH) are present in the resistance to thyroid hormone syndrome. A mild acquired resistance to thyroid hormone might occur in the general population and be associated with diabetes. We aimed to analyze the association of resistance to thyroid hormone indices (the Thyroid Feedback Quantile-based Index [TFQI], proposed in this work, and the previously used Thyrotroph T4 Resistance Index and TSH Index) with diabetes. RESEARCH DESIGN AND METHODS: We calculated the aforementioned resistance to thyroid hormone indices based on a U.S. representative sample of 5,129 individuals ≥20 years of age participating in the 2007-2008 National Health and Nutrition Examination Survey (NHANES). Also, to approximate TFQI, a U.S.-referenced Parametric TFQI (PTFQI) can be calculated with the spreadsheet formula =NORM.DIST(fT4_cell_in_pmol_per_L,10.075,2.155,TRUE)+NORM.DIST(LN(TSH_cell_in_mIU_per_L),0.4654,0.7744,TRUE)-1. Outcomes of interest were glycohemoglobin ≥6.5%, diabetes medication, diabetes-related deaths (diabetes as contributing cause of death), and additionally, in a fasting subsample, diabetes and metabolic syndrome. Logistic and Poisson regressions were adjusted for sex, age, and race/ethnicity. RESULTS: Odd ratios for the fourth versus the first quartile of TFQI were 1.73 (95% CI 1.32, 2.27) (P trend = 0.002) for positive glycohemoglobin and 1.66 (95% CI 1.31, 2.10) (P trend = 0.001) for medication. Diabetes-related death rate ratio for TFQI being above versus below the median was 4.81 (95% CI 1.01, 22.94) (P trend = 0.015). Further adjustment for BMI and restriction to normothyroid individuals yielded similar results. Per 1 SD in TFQI, odds increased 1.13 (95% CI 1.02, 1.25) for diabetes and 1.16 (95% CI 1.02, 1.31) for metabolic syndrome. The other resistance to thyroid hormone indices showed similar associations for diabetes-related deaths and metabolic syndrome. CONCLUSIONS: Higher values in resistance to thyroid hormone indices are associated with obesity, metabolic syndrome, diabetes, and diabetes-related mortality. Resistance to thyroid hormone may reflect energy balance problems driving type 2 diabetes. These indices may facilitate monitoring treatments focused on energy balance.
Assuntos
Diabetes Mellitus Tipo 2/epidemiologia , Síndrome Metabólica/epidemiologia , Síndrome da Resistência aos Hormônios Tireóideos/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/complicações , Feminino , Humanos , Hipertireoidismo/complicações , Hipertireoidismo/epidemiologia , Hipotireoidismo/sangue , Hipotireoidismo/complicações , Hipotireoidismo/epidemiologia , Incidência , Masculino , Síndrome Metabólica/sangue , Síndrome Metabólica/complicações , Pessoa de Meia-Idade , Mortalidade , Inquéritos Nutricionais , Obesidade/sangue , Obesidade/complicações , Obesidade/epidemiologia , Prevalência , Síndrome da Resistência aos Hormônios Tireóideos/sangue , Síndrome da Resistência aos Hormônios Tireóideos/complicações , Síndrome da Resistência aos Hormônios Tireóideos/diagnóstico , Hormônios Tireóideos/sangue , Tireotropina/sangue , Estados Unidos/epidemiologia , Adulto JovemRESUMO
BACKGROUND: The aim of this study was to compare fourteen non-invasive indexes/scores: AAR, APRI, Fibroindex, MODEL3, Forns index, FIB4, GUCI, FI, FCI, Pohl score, AP index, CDS, HGM-1 and HGM-2, in order to diagnose the hepatic fibrosis stage in a survey of patients with chronic hepatitis C. METHODS: 84 patients with chronic hepatitis C were studied. Liver fibrosis was staged according to the Scheuer scoring system. The diagnostic accuracy of these indexes/scores was evaluated by AUROC, contingency tables and logistic regression analysis. RESULTS: The best AUROCs (>0.9) to discriminate cirrhosis (F=4), were observed for CDS, FI, AAR, MODEL3, FIB4, HGM-2 and FCI. To discriminate at least advance fibrosis (F≥3), the best AUROCs (>0.89) were for CDS, FI, FIB4, HGM2-2, MODEL3 and FCI. To discriminate at least significant fibrosis (F≥2), the best AUROCs (>0.8) were for FIB4, GUCI, APRI, FI, Forns index, HGM-2 and FCI. Contingency tables and logistic regression analysis supported the results obtained by AUROC. CONCLUSIONS: This study compares the diagnostic performance of fourteen indexes for the diagnosis of liver fibrosis stage in the same group of CHC patients. These results allow the selection of the best indexes for further studies in larger populations, in order to build diagnostic algorithms as an alternative to liver biopsy for fibrosis staging in patients with chronic HCV infection. These algorithms would allow to take therapeutical decisions and the continuous follow-up of hepatic fibrosis in these patients.
Assuntos
Biomarcadores/sangue , Hepatite C Crônica/complicações , Cirrose Hepática/diagnóstico , Adulto , Feminino , Seguimentos , Hepacivirus/isolamento & purificação , Humanos , Cirrose Hepática/sangue , Cirrose Hepática/etiologia , Masculino , Valor Preditivo dos Testes , Estudos Prospectivos , Curva ROC , Índice de Gravidade de DoençaRESUMO
The aim of this article is to investigate clinical research on indications, posology, efficacy, and safety of epidermal growth factor (EGF) eye drops in the treatment of some human corneal disorders. Methods used include systematic search and selection of series of cases and clinical trials in Medline database up to January 2012, kappa index (K) to validate retrieval information, cumulative Mantel-Haenszel-stratified meta-analysis, 2×2 contingency table of randomized EGF-vehicle-controlled treated groups, and statistical program SPSSv12. Our results indicate that EGF eye drops appear to be a very effective treatment of acute heterogeneous corneal diseases, without significant adverse effects, with a 86.8% clinical efficacy reported by authors, a 98% (P<0.05) probabilistic expected efficacy, and 51.3 (17.4-148.7 confidence interval 95%; P<0.05) odds ratio EGF/vehicle. However, clinical trials are scarce, with low sample sizes and serious inconsistencies in EGF posology. EGF eye drops (50-1,000 ng, 2-3 times/day) could be a useful treatment for promoting postoperative refractive surgery, reversing cases of keratopathy secondary to systematic EGF receptor inhibitors, diabetic keratopathy, and other corneal and conjunctival disorders.
Assuntos
Córnea/efeitos dos fármacos , Doenças da Córnea/tratamento farmacológico , Fator de Crescimento Epidérmico , Doença Aguda , Córnea/patologia , Doenças da Córnea/epidemiologia , Doenças da Córnea/etiologia , Doenças da Córnea/patologia , Relação Dose-Resposta a Droga , Fator de Crescimento Epidérmico/administração & dosagem , Fator de Crescimento Epidérmico/efeitos adversos , Fator de Crescimento Epidérmico/uso terapêutico , Humanos , Modelos Logísticos , Razão de Chances , Soluções Oftálmicas , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento , Cicatrização/efeitos dos fármacosRESUMO
Determinar el estadio de fibrosis hepática es esencial en el manejo de la enfermedad hepática en pacientes con hepatitis crónica por virus C. La biopsia hepática ha sido considerada el gold standard para diagnosticar la enfermedad, la actividad necroinflamatoria y el estadio de fibrosis, pero tiene algunas limitaciones técnicas y riesgos. Teniendo en cuenta estas limitaciones, existe cierta exigencia en introducir biomarcadores séricos no invasivos para el diagnóstico de fibrosis que podrían ser capaces de reemplazar parcialmente a la biopsia hepática. El biomarcador sérico ideal debería ser específico para el hígado y fácil de determinar. Los marcadores séricos se dividen en directos e indirectos. Los directos reflejan el recambio de la matriz extracelular, mientras que los indirectos reflejan alteraciones en la función hepática. Aunque todavía está limitado el grado de implementación de los test no invasivos de fibrosis hepática, esta revisión es una visión de conjunto de los biomarcadores, índices y algoritmos diagnósticos de fibrosis hepática estudiados en hepatitis crónica C pero con un interés potencial en otras hepatopatías crónicas (AU)
Precise staging of liver fibrosis is essential in the management of liver disease activity in chronic hepatitis C patients. Liver biopsy has been considered the reference method for diagnosing disease, grading necroinflammatory activity, and staging fibrosis, but it has some technical limitations and risks. Taking into account these limitations, there is a need to introduce non-invasive serum markers for fibrosis that would be able to partially replace liver biopsy. Ideal serum markers should be specific for the liver and easy to perform. Serum markers of hepatic fibrosis are divided into direct and indirect. Direct markers reflect extracellular matrix turnover, whereas indirect markers reflect alterations in hepatic function. The degree of implementation of non-invasive diagnostic tests for liver fibrosis still remains limited. This review provides a current overview of biomarkers, indexes and algorithms for hepatic fibrosis diagnosis in chronic hepatitis C patients (AU)
Assuntos
Feminino , Humanos , Masculino , Biomarcadores/análise , Biomarcadores/metabolismo , Cirrose Hepática/diagnóstico , Hepatite Crônica/diagnóstico , Hepatite C/diagnóstico , Metaloproteases , Fator de Crescimento Transformador beta1 , Fibrose/diagnóstico , Algoritmos , Biomarcadores/sangue , Ensaios de Anticorpos Bactericidas Séricos/métodos , Pró-Colágeno , Ácido Hialurônico , Receptores de Fibrinogênio/análiseRESUMO
The low incidence of cardiovascular disease in countries bordering the Mediterranean basin, where olive oil is the main source of dietary fat, has stimulated interest in the chemical composition of olive oil and in the production of other oils enriched with its minor components. This review summarizes what has been learned about the effects of different olive oil preparations on the development of atherosclerosis and about the prognostic value of associated plasma variables in the disease from experiments on genetically modified mice that spontaneously develop atherosclerosis. The limitations of this animal model associated with its morphological and physiological differences with humans are minimized by the similarity of the two genomes and by the potential for increased understanding attainable, given that the dietary interventions reported here would have taken 400 years to achieve in humans. As observed in traditional Mediterranean populations, it has been confirmed that extra virgin olive oil is beneficial when consumed judiciously and in a diet that is low in cholesterol due to the relative scarcity of animal products. Furthermore, the use of genomic techniques has led to the identification of new markers of response to olive oil. In conclusion, multidisciplinary research into extra virgin olive oil is expanding our knowledge of the substance's biological properties.
Assuntos
Apolipoproteínas E/genética , Apolipoproteínas E/fisiologia , Óleos de Plantas/farmacologia , Tecido Adiposo/metabolismo , Animais , Aterosclerose/epidemiologia , Aterosclerose/etiologia , Dieta Mediterrânea , Gorduras na Dieta , Humanos , Fígado/metabolismo , Camundongos , Camundongos Knockout , Azeite de Oliva , Óleos de Plantas/químicaRESUMO
La baja incidencia de enfermedades cardiovascularesen los países de la Cuenca Mediterránea, donde elaceite de oliva es la principal fuente de grasa en la alimentación,ha motivado un mejor conocimiento de sucomposición química y el desarrollo de aceites enriquecidosen sus componentes minoritarios. En esta revisiónse recopilan los efectos de diferentes preparaciones delaceite de oliva sobre el desarrollo de la aterosclerosis yel valor pronóstico para la enfermedad de los parámetrosplasmáticos mediante el empleo de un ratón modificadogenéticamente en el que ésta se desarrolla espontáneamente.Las limitaciones del modelo por sus diferenciasmorfológicas y fisiológicas con el hombre se minimizanante la similitud de ambos genomas y el avance de conocimientoque posibilita, ya que efectuar en humanoslas intervenciones recopiladas habría requerido 400 años.Confirmando la tradición de los pueblos mediterráneos,se ha verificado la eficacia del aceite de oliva virgen consumidoprudentemente y en dietas con bajo contenido encolesterol por la relativa escasez de productos de origenanimal. Además, la exploración con herramientas de genómicaha identificado nuevos marcadores de respuestaal aceite. En conclusión, la investigación multidisciplinariadel aceite de oliva virgen extra permite ampliar el conocimientode sus propiedades biológicas (AU)
The low incidence of cardiovascular disease in countriesbordering the Mediterranean basin, where olive oil is themain source of dietary fat, has stimulated interest in thechemical composition of olive oil and in the productionof other oils enriched with its minor components.This review summarizes what has been learned aboutthe effects of different olive oil preparations on thedevelopment of atherosclerosis and about the prognosticvalue of associated plasma variables in the diseasefrom experiments on genetically modified mice thatspontaneously develop atherosclerosis. The limitations ofthis animal model associated with its morphological andphysiological differences with humans are minimized bythe similarity of the two genomes and by the potential forincreased understanding attainable, given that the dietaryinterventions reported here would have taken 400 years toachieve in humans. As observed in traditional Mediterraneanpopulations, it has been confirmed that extra virgin olive oilis beneficial when consumed judiciously and in a diet thatis low in cholesterol due to the relative scarcity of animalproducts. Furthermore, the use of genomic techniqueshas led to the identification of new markers of responseto olive oil. In conclusion, multidisciplinary research intoextra virgin olive oil is expanding our knowledge of thesubstances biological properties (AU)